DE HAAS, Sanne Lysbet SL,‧德哈斯,DELMAR, Paul P,‧德爾馬,FOERNZLER, Dorothee D,‧福爾恩茲勒,KLAUSE, Ursula U,‧克勞斯,SCHERER, Stefan S,‧謝勒
申请号：
HK16105145.5
公开号：
HK1217093A
申请日:
2013.10.30
申请国别(地区):
HK
年份:
2016
代理人:
摘要：
The present invention provides methods for improving the treatment effect of a chemotherapy regimen of a patient suffering from breast cancer, in particular locally advanced, recurrent or metastatic HER-2 negative breast cancer, by adding bevacizumab (Avastin TM ) to a chemotherapy regimen by determining the expression level, in particular the blood plasma expression level, of one or more of VEGFA, VEGFR2 and PLGF relative to control levels of patients diagnosed with breast cancer, in particular locally advanced, recurrent or metastatic HER-2 negative breast cancer. In particular, the present invention provides methods of improving the treatment effect, wherein the treatment effect is the progression-free survival of the patient. The present invention further provides for methods for assessing the sensitivity or responsiveness of a patient to bevacizumab (Avastin TM ) in combination with a chemotherapy regimen, by determining the expression level, in particular the blood plasma expression level, of one or more of VEGFA, VEGFR2 and PLGF relative to control levels in patients diagnosed with breast cancer, in particular locally advanced, recurrent or metastatic HER-2 negative breast cancer.
